Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 3, 2002, Pages 527-532

  Di Caro, S ^a   Ojetti, V ^a   Zocco, M A ^a   Cremonini, F ^a   Bartolozzi, F ^b   Candelli, M ^a   Lupascu, A ^a   Nista, E C ^a   Cammarota, G ^a   Gasbarrini, A ^a,b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; LANSOPRAZOLE; MOXIFLOXACIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; HEART PALPITATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CLARITHROMYCIN; DRUG COMBINATIONS; FEMALE; FLUOROQUINOLONES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PATIENT COMPLIANCE; QUINOLINES; TREATMENT OUTCOME;

EID: 0036191977     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01165.x     Document Type: Article

References (46)

1. Short-term low-dose therapy for the eradication of Heficobacter pylori
2. A systematic review of Helicobacter pylori eradication therapy. The impact of antimicrobial resistance on eradication rates
3. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: Preliminary experience
4. Rifabutin-based rescue therapy for Helicobacter pylori infected patients alter failure of standard regimens
5. Letter to editors: Rifabutin-based Helicobacter pylori eradication rescue therapy
6. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection
7. Preclinical evaluation of moxifloxacin, a novel fluoroquinolone
8. Moxifloxacin Bayer
9. Moxifloxacin: An 8-methoxyquinolone antibacterial with enhanced potency
10. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: A review of microbiologic and pharmacokinetic-pharmacody namic characteristics
11. Moxifloxacin: A review of its clinical potential in the management of community-acquired respiratory tract infections
12. The safety profile of the fluoroquinolones
13. Ouinolone activity against anaerobes
14. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms
15. Fluoroquinolones-induced renal failure
16. Comparison of an in vitro cellular phototoxicity model against controlled clinical trials of fluoroquinolone skin phototoxicity
17. Adverse reactions to fluoroquinolones. An overview on mechanistic aspects
18. Comparative effects of moxifioxacin and clarithromycin on the normal intestinal microflora
19. Effect of quinolones on intestinal ecology
20. Pharmacokinetics of once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone
21. Moxifloxacin
22. Penetration of moxifloxacin into peripheral compartments in humans
23. Moxifloxacin: A review of the microbiological, pharmacological, clinical and safety features
24. The proton pump inhibitors: Similarities and differences
25. Review article: Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors
26. Safety profile of soprazole: The US clinical trial experience
27. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders
28. Validation of the 13C-urea breath test for the diagnosis of Helicobacter pylori infection in children: A multicenter study
29. Urea breath tests in the management of Helicobacter pylori infection
30. Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens
31. Helicobacter pylori: Past, present and future
32. Helicobacter pylorirelated extradigestive diseases and effects of eradication therapy
33. Extradigestive manifestations of Helicobacter pylori gastric infection
34. Current European concepts in the management of Helicobacter pylori infection. The maastricht consensus report
35. New concepts concerning management of Helicobacter pylori infection: 2 years after the maastricht consensus report
36. Antibiotic resistance in Helicobacter pylori: Implications for therapy
37. Italian omeprazole triple therapy: A 1 week regimen
38. Nitroimidazole resistance in Helicobacter pylori
39. Treatment failure: The problem of non-responders
40. The impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy
41. Efficacy of a multistep strategy for Helicobacter pylori eradication
42. Highly selective antibacterial activity of novel alkyl quinolone alkaloids from a Chinese herbal medicine, Gosyuyu (Wu-Chu-Yu). Against Helicobacter pylori in vitro
43. Susceptibility of Helicobacter pylori to mupirocin, oxazolidones, quinupristin/dalfopristin and new quinolones
44. Intracellular targets of moxifloxacin: A comparison with other fluoroquinolones
45. Effects of subinhibitory concentrations of moxifloxacin in an in-vitro dynamic model
46. Bactericidal properties of moxifloxacin and post-antibiotic effect